IBRX

$0.00

(

+0.00%

)
Quote details

stock

Immunitybio Inc

NASDAQ | IBRX

2.15

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 5, 2025)

$2.05B

Market Cap

-

P/E Ratio

-0.44

EPS

$5.88

52 Week High

$1.83

52 Week Low

HEALTHCARE

Sector

IBRX Chart

Recent Chart
Price Action

IBRX Technicals

Tags:

IBRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $15M
Total Revenue $15M
Cost Of Revenue $18M
Costof Goods And Services Sold $18M
Operating Income -$344M
Selling General And Administrative $169M
Research And Development $190M
Operating Expenses $359M
Investment Income Net -
Net Interest Income -$152M
Interest Income $2.4M
Interest Expense $154M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$414M
Income Tax Expense $81K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$259M
Ebitda -$242M
Net Income -$414M

Revenue & Profitability

Earnings Performance

IBRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $383M
Total Current Assets $185M
Cash And Cash Equivalents At Carrying Value $143M
Cash And Short Term Investments $143M
Inventory $8.3M
Current Net Receivables $2.7M
Total Non Current Assets $198M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $15M
Intangible Assets Excluding Goodwill $15M
Goodwill $910K
Investments -
Long Term Investments $0
Short Term Investments $6.4M
Other Current Assets $24M
Other Non Current Assets -
Total Liabilities $871M
Total Current Liabilities $55M
Current Accounts Payable $6.7M
Deferred Revenue -
Current Debt -
Short Term Debt $8.7M
Total Non Current Liabilities $816M
Capital Lease Obligations $42M
Long Term Debt $462M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $504M
Other Current Liabilities $39M
Other Non Current Liabilities $285M
Total Shareholder Equity -$488M
Treasury Stock -
Retained Earnings -$3.4B
Common Stock $85K
Common Stock Shares Outstanding $700M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$391M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $18M
Capital Expenditures $6.9M
Change In Receivables -
Change In Inventory -$8.3M
Profit Loss -
Cashflow From Investment -$12M
Cashflow From Financing $282M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$414M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $15M
Total Revenue $15M
Cost Of Revenue $18M
Costof Goods And Services Sold $18M
Operating Income -$344M
Selling General And Administrative $169M
Research And Development $190M
Operating Expenses $359M
Investment Income Net -
Net Interest Income -$152M
Interest Income $2.4M
Interest Expense $154M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$414M
Income Tax Expense $81K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$259M
Ebitda -$242M
Net Income -$414M

IBRX News

IBRX Profile

Immunitybio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

ImmunityBio, Inc. is a pioneering immunotherapy company focused on developing innovative treatments utilizing memory T-cells to combat a wide range of cancer types. The company's proprietary cancer vaccine aims to create an effective therapeutic approach that minimizes the reliance on high-dose chemotherapy while enhancing the body's immune response against tumors. By leveraging advanced biotechnology, ImmunityBio strives to transform cancer treatment and improve patient outcomes, positioning itself as a key player in the evolving landscape of oncology.

CHR
-45.58%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
VHAI
0.00%
$0.00
PFE
+1.37%
$24.63
RUBI
-49.75%
$0.30
SNAP
-2.00%
$7.32
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
SLDP
+51.55%
$8.51
YDKG
-5.55%
$0.05
ETHD
+20.91%
$5.26
F
+2.69%
$13.13
SMX
+38.80%
$2.04
PLTR
-1.48%
$187.90
T
-0.36%
$24.44
DNN
-2.18%
$2.68
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
PINS
-22.92%
$25.36
ACHR
+0.26%
$9.58
GPUS
-7.02%
$0.34
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
CMBM
+58.82%
$3.24
ONDS
+0.67%
$6.00
WTO
-0.20%
$0.04
CIFR
+9.77%
$24.71
SOFI
+2.38%
$30.07
RXRX
-0.80%
$4.96
SMCI
-11.11%
$42.13
TEVA
+20.16%
$24.58
INTC
+3.96%
$38.50
BAC
-2.04%
$52.44
AMZN
-1.84%
$249.32
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
NFE
+13.99%
$1.53
AMCR
+3.04%
$8.11
BTG
+1.12%
$4.04
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
MARA
+3.06%
$17.13
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
CAN
+16.21%
$1.29
RIG
-0.12%
$3.89
U
+18.12%
$42.37
RGTI
+5.99%
$37.29
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
FUBO
+11.00%
$4.08
ADD
-25.47%
$0.05
BURU
-2.17%
$0.28
EPWK
-6.41%
$0.07
NVO
+0.43%
$48.46
QS
+9.93%
$16.97
WULF
+2.46%
$15.38
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
RIOT
-1.58%
$18.97
ZDAI
+13.94%
$0.52
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
CMG
+0.72%
$31.97
APPS
+23.14%
$7.29
HTZ
-0.81%
$6.67
ALIT
-7.22%
$2.50
QBTS
+4.37%
$31.04
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
GOOGL
+2.43%
$284.31
NIO
+2.30%
$7.32
BBD
+3.37%
$3.52
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
CGC
-5.83%
$1.12
HPE
+0.59%
$23.70
PCG
+1.05%
$16.32
AG
-7.82%
$10.65
PLTZ
+2.80%
$6.24
GGB
+5.11%
$3.59
ETWO
0.00%
$3.30
HBAN
+0.13%
$15.29
HOOD
-6.98%
$136.80
PBR
+2.57%
$12.13
ITUB
+1.55%
$7.49
MSPR
-27.89%
$0.47
AAPL
-0.18%
$269.53
CHR
-45.58%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
VHAI
0.00%
$0.00
PFE
+1.37%
$24.63
RUBI
-49.75%
$0.30
SNAP
-2.00%
$7.32
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
SLDP
+51.55%
$8.51
YDKG
-5.55%
$0.05
ETHD
+20.91%
$5.26
F
+2.69%
$13.13
SMX
+38.80%
$2.04
PLTR
-1.48%
$187.90
T
-0.36%
$24.44
DNN
-2.18%
$2.68
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
PINS
-22.92%
$25.36
ACHR
+0.26%
$9.58
GPUS
-7.02%
$0.34
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
CMBM
+58.82%
$3.24
ONDS
+0.67%
$6.00
WTO
-0.20%
$0.04
CIFR
+9.77%
$24.71
SOFI
+2.38%
$30.07
RXRX
-0.80%
$4.96
SMCI
-11.11%
$42.13
TEVA
+20.16%
$24.58
INTC
+3.96%
$38.50
BAC
-2.04%
$52.44
AMZN
-1.84%
$249.32
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
NFE
+13.99%
$1.53
AMCR
+3.04%
$8.11
BTG
+1.12%
$4.04
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
MARA
+3.06%
$17.13
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
CAN
+16.21%
$1.29
RIG
-0.12%
$3.89
U
+18.12%
$42.37
RGTI
+5.99%
$37.29
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
FUBO
+11.00%
$4.08
ADD
-25.47%
$0.05
BURU
-2.17%
$0.28
EPWK
-6.41%
$0.07
NVO
+0.43%
$48.46
QS
+9.93%
$16.97
WULF
+2.46%
$15.38
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
RIOT
-1.58%
$18.97
ZDAI
+13.94%
$0.52
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
CMG
+0.72%
$31.97
APPS
+23.14%
$7.29
HTZ
-0.81%
$6.67
ALIT
-7.22%
$2.50
QBTS
+4.37%
$31.04
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
GOOGL
+2.43%
$284.31
NIO
+2.30%
$7.32
BBD
+3.37%
$3.52
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
CGC
-5.83%
$1.12
HPE
+0.59%
$23.70
PCG
+1.05%
$16.32
AG
-7.82%
$10.65
PLTZ
+2.80%
$6.24
GGB
+5.11%
$3.59
ETWO
0.00%
$3.30
HBAN
+0.13%
$15.29
HOOD
-6.98%
$136.80
PBR
+2.57%
$12.13
ITUB
+1.55%
$7.49
MSPR
-27.89%
$0.47
AAPL
-0.18%
$269.53

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.